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Original article
Secukinumab sustains improvement in signs and
symptoms of psoriatic arthritis: 2 year results from
the phase 3 FUTURE 2 study
Iain B. McInnes1, Philip J. Mease2, Christopher T. Ritchlin3, Proton Rahman4,
Alice B. Gottlieb5, Bruce Kirkham6, Radhika Kajekar7,
Eumorphia-Maria Delicha8, Luminita Pricop7 and Shephard Mpofu8
Abstract
Objectives. To assess long-term efficacy, safety and tolerability of secukinumab up to 104 weeks in
patients with active PsA.
Methods. Patients with PsA (n= 397) were randomized to s.c. secukinumab 300, 150 or 75 mg or placebo at
baseline, weeks 1, 2, 3 and 4 and every 4 weeks thereafter. Placebo-treated patients were re-randomized to
receive secukinumab 300 or 150 mg s.c. from week 16 (placebo non-responders) or week 24 (placebo
responders). Exploratory endpoints at week 104 included 20, 50 and 70% improvement in ACR criteria
(ACR20, 50, 70); 75 and 90% improvement in the Psoriasis Area Severity Index, 28-joint DAS with CRP,
presence of dactylitis and enthesitis and other patient-reported outcomes. For binary variables, missing
values were imputed; continuous variables were analysed by a mixed-effects model for repeated measures.
Results. A total of 86/100 (86%), 76/100 (76%) and 65/99 (66%) patients in the secukinumab 300, 150
and 75 mg groups, respectively, completed 104 weeks. At week 104, ACR20 response rates after multiple
imputation in the 300, 150 and 75 mg groups were 69.4, 64.4 and 50.3%, respectively. Sustained clinical
improvements were observed through week 104 with secukinumab across other clinically important do-
mains of PsA. Responses were sustained through week 104 regardless of prior anti-TNF-a use. Over the
entire treatment period the incidence, type and severity of adverse events were consistent with those
reported previously.
Conclusion. Secukinumab provided sustained improvements in signs and symptoms and multiple clinical
domains in patients of active PsA through 2 years of therapy. Secukinumab was well tolerated, with a
safety profile consistent with that reported previously.
Trial registration: ClinicalTrials.gov (https://clinicaltrials.gov), NCT01752634
Key words: spondyloarthritis, psoriatic arthritis, biological therapies, anti-TNF therapy, interleukin, long term,
efficacy, safety, joints, swelling
Rheumatology key messages
. Secukinumab provided rapid improvements sustained through 2 years in multiple clinical domains of PsA.
. Clinical improvements with secukinumab were observed in PsA patients regardless of prior anti-TNF exposure.
. Secukinumab was well tolerated in PsA, with a safety profile consistent with that reported previously.
1Institute of Infection Immunity and Inflammation, University of
Glasgow, Glasgow, UK, 2Division of Rheumatology Clinical Research,
Swedish Medical Centre and University of Washington, Seattle, WA,
3Allergy/Immunology and Rheumatology Division, University of
Rochester, Rochester, NY, USA, 4Faculty of Medicine, Memorial
University, St. John’s, NL, Canada, 5Department of Dermatology, New
York Medical College, Valhalla, NY, USA, 6Rheumatology Department,
Guy’s & St Thomas’ NHS Foundation Trust, London, UK, 7Novartis
Pharmaceuticals Corporation, East Hanover, NJ, USA and 8Novartis
Pharma, Basel, Switzerland
Correspondence to: Iain B. McInnes, Institute of Infection Immunity
and Inflammation, College of Medical, Veterinary and Life Sciences,
University of Glasgow, 120 University Place, Glasgow G12 8TA, UK.
E-mail: Iain.McInnes@glasgow.ac.uk
Submitted 13 February 2017; revised version accepted 28 June 2017
! The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use,
distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
RHEUMATOLOGY
Rheumatology 2017;56:19932003
doi:10.1093/rheumatology/kex301
Advance Access publication 16 August 2017
C
L
IN
IC
A
L
S
C
IE
N
C
E
Introduction
PsA is a chronic, immune-mediated, inflammatory dis-
ease characterized by peripheral and axial arthritis, dac-
tylitis and enthesitis that affects 30% of psoriasis
patients and comprises up to 1% of the general popula-
tion [13].
Biologic therapies such as anti-TNF-a and anti-IL-17A
antibodies are recommended for the treatment of PsA if
an inadequate response is noted to first-line treatment
with NSAIDs and/or DMARDs [4, 5]. TNF-a inhibitors im-
prove the signs and symptoms of PsA, reduce structural
damage and enhance patient-reported measures of qual-
ity of life (QoL) [6, 7]. However, not all patients respond to
or tolerate anti-TNF-a therapy; in some patients, response
is lost over time. There remains significant unmet clinical
need in PsA [8, 9].
Secukinumab, a high-affinity, fully human IgG1 mAb
that selectively binds to and neutralizes IL-17A, has
shown efficacy in treating immune-mediated inflammatory
diseases such as psoriasis [4, 1015], AS and PsA
[1618].
In the FUTURE 1 study (NCT01392326), secukinumab,
administered with i.v. loading and s.c. maintenance
dosing, demonstrated a rapid onset of efficacy and was
shown to be superior to placebo in the treatment of pa-
tients with PsA through multiple components of the dis-
ease, including the arthritis and skin signs and symptom
measures, structural damage and physical function in a
population comprised of 70% patients naive to anti-TNF-a
and 30% patients who were inadequate responders or
intolerant to anti-TNF-a (anti-TNF-a-IR) therapy. Long-
term efficacy with secukinumab was also demonstrated
in the study through the maintenance of 20, 50 and
70% improvement in ACR criteria (ACR20, 50, 70) up to
week 104 accompanied by significant and sustained in-
hibition of joint structural damage based on radiographic
data [19].
Secukinumab, given via s.c. self-administration loading
and maintenance dosing, significantly and rapidly improved
the signs and symptoms of PsA at week 24 sustained
through week 52 in the primary analysis of the phase 3
FUTURE 2 study (NCT01752634). FUTURE 2 is the first
large study to report that inhibiting IL-17A with s.c. secuki-
numab provides significant and sustained improvements in
important clinical domains of PsA, including joint and skin
symptoms, physical function and QoL. Importantly, clinical
benefits were demonstrated in both anti-TNF-a-naive and
anti-TNF-a-IR patients. The results highlighted the key role
of IL-17A in the pathogenesis of PsA and confirmed the
potential of secukinumab as a novel therapy for patients
with this disease [18].
Here we provide data describing the efficacy and safety
of secukinumab through 104 weeks in the FUTURE 2
study that demonstrate the long-term (2 year) efficacy
and safety results of secukinumab in patients with active
PsA despite current or previous NSAIDs, DMARDs and/or
anti-TNF-a therapy.
Methods
Study design
FUTURE 2 is an ongoing, multicentre, randomized,
double-blind, parallel-group, placebo-controlled study,
the design of which has been published in detail [18]. In
brief, patients with active PsA were randomized (1:1:1:1)
to receive s.c. secukinumab (300, 150 or 75 mg) or pla-
cebo at baseline, weeks 1, 2, 3 and 4 and every 4 weeks
thereafter. Placebo patients were re-randomized to re-
ceive secukinumab 300 or 150 mg s.c. every 4 weeks de-
pending upon ACR20 response at week 16; patients were
classified as responders (520% improvement from base-
line in tender and swollen joint counts) or non-responders,
with non-responders switching at week 16 and re-
sponders at week 24. Randomization was stratified, as
pre-specified, by anti-TNF-a status (anti-TNF-a-naive
and anti-TNF-a-IR) with 40% of randomized patients
planned to be anti-TNF-a-IR.
The study was conducted in accordance with the prin-
ciples of the Declaration of Helsinki [20], International
Conference of Harmonization Good Clinical Practice and
all applicable laws and regulations. All centres received
approval from an independent ethics committee or insti-
tutional review board. Patients provided written informed
consent before the study-related procedures were
undertaken.
Patients
Key inclusion criteria
Adult patients with active disease, who met the ClASsifi-
cation criteria for Psoriatic ARthritis, despite previous
treatment with NSAIDs, DMARDs and/or anti-TNF-a
agents were included. Patients who had previously used
up to three anti-TNF-a agents could enrol if they had an
inadequate response or had stopped treatment because
of safety or tolerability reasons.
Key exclusion criteria
Previous use of any biologic agent other than anti-TNF-a
agents; active inflammatory diseases other than PsA;
active infection 2 weeks before randomization or a history
of ongoing, chronic or recurrent infections; history of ma-
lignant disease within the past 5 years (excluding basal
cell carcinoma or actinic keratosis, in situ cervical cancer
or non-invasive malignant colon polyps) and pregnancy
were considered as exclusion criteria.
A detailed description of the patient inclusion and ex-
clusion criteria has been reported previously [18].
Outcomes
The primary efficacy endpoint was the proportion of pa-
tients achieving ACR20 response at week 24. Secondary
objectives included the efficacy of secukinumab versus
placebo at week 24 in ACR50 response; 75 and 90% im-
provement in the Psoriasis Area Severity Index (PASI 75
and 90) in patients with psoriasis affecting 53% of
the body surface area (BSA); change from baseline in
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the 28-joint DAS including levels of CRP (DAS28-CRP)
and the incidence of dactylitis and enthesitis. QoL was
measured as the change from baseline in the Medical
Outcomes Study 36-Item Short-Form Health Survey (SF-
36) physical component summary (PCS) score. Physical
function was assessed as the change from baseline in the
HAQ Disability Index (HAQ-DI) score. ACR70 response at
week 24 was an exploratory endpoint [18]. For the 2 year
analysis, exploratory analysis of all primary and secondary
endpoints continued to week 104. Exploratory endpoints
assessed at week 104 are based on patients originally
randomized to secukinumab at the beginning of the trial
and included ACR20/50/70, PASI 75/90, DAS28-CRP, SF-
36 PCS, HAQ-DI and resolution of dactylitis and enthesi-
tis. The other patient-reported outcomes (PROs) and QoL
measures assessed at week 104 included patient global
assessment of disease activity, patient assessment of
PsA pain by visual analogue scale (VAS), SF-36 mental
component summary (MCS), Work Productivity And
Activity ImpairmentGeneral Health, Dermatology Life
Quality Index, Functional Assessment of Chronic Illness
TherapyFatigue and the European Quality of Life
5-Dimensions (EQ-5D) health status questionnaire. All
PROs were analysed in the full analysis set that comprised
all randomized patients to whom study treatment had
been assigned and entered the long-term extension.
The overall safety and tolerability was assessed by
monitoring the frequency of adverse events (AEs),
abnormalities in laboratory findings, ECG findings and
vital signs. Biochemical investigations were classified
according to the Common Terminology Criteria for
Adverse Events (version 4) [21]. Blood samples were
collected at baseline, immediately before dosing at
week 24 and at week 104 for the assessment of secu-
kinumab immunogenicity using a Meso Scale Discovery
bridging immunoassay (Meso Scale Diagnostics,
Rockville, MD, USA) [22].
Statistical analysis
The details of sample size calculation and analysis of pri-
mary and other efficacy endpoints have been reported
previously [18]. Briefly, a sample size of 100 patients per
group was estimated to provide about 92% power to
detect a treatment difference of 26% for the primary end-
point of ACR20 response at week 24 with Fisher’s exact
test and about 80% power for secondary endpoints. In the
current analysis, missing binary variables up to week 104
were imputed using multiple imputation. Summary statis-
tics are based on observed and imputed data. Continuous
variables were analysed using a mixed-effects model for
repeated measures, with treatment group, assessment
visit and anti-TNF-a response status as factors, weight
and baseline score as continuous covariates and treat-
ment by analysis visit as well as baseline score by analysis
visit as interaction terms. Results are given in mean (S.D.)
or least squares mean (S.E.), as appropriate. Evaluations of
efficacy were performed on the full analysis set. Dactylitis
and enthesitis, when multiple imputation was considered,
were evaluated in the subgroup of patients with these
symptoms at baseline. PASI assessment was evaluated
in the subgroup with at least 3% of the BSA affected by
psoriatic skin involvement. Predefined subgroup analyses
were carried out on the basis of previous anti-TNF-a ther-
apy and concomitant MTX treatment for key efficacy end-
points. The safety analysis included all patients who
received one or more doses of secukinumab and data
presented as exposure-adjusted incidence rates (EAIRs)
per 100 patient-years.
Results
Patients
Of the 397 patients randomized overall, 335 (84%) com-
pleted 52 weeks of study. Eighty-six (86%), 76 (76%) and
65 (66%) patients in the secukinumab 300, 150 and 75 mg
groups, respectively, completed 104 weeks of treatment
(Fig. 1).
At baseline, demographic and disease characteristics
were similar across groups: 184 (46%) of 397 randomized
patients had psoriasis on at least 3% of their BSA, 258
(65%) were anti-TNF-a-naive and 185 (47%) and 81 (20%)
received concomitant MTX and systemic glucocorticoid,
respectively [18].
Discontinuation of study treatment
Of 299 patients originally randomized to secukinumab,
14/100 (14%), 24/100 (24%) and 34/99 (34%) patients
discontinued the study treatment by week 104 in the
secukinumab 300, 150 and 75 mg groups, respectively,
of which 8 (8%), 14 (14%) and 24 (24%) patients, respect-
ively, discontinued treatment by week 52. At week 104,
3/100 (3%), 7/100 (7%) and 17/99 (17%) patients had
discontinued the treatment citing lack of efficacy, which
was the most common cause of discontinuation in the
secukinumab 300, 150 and 75 mg groups, respectively.
In these three groups, 3/100 (3%), 6/100 (6%) and 5/99
(5%) patients discontinued due to an AE in the secukinu-
mab 300, 150 and 75 mg groups, respectively.
Efficacy
At week 104, ACR20 response rates in the secukinumab
300, 150 and 75 mg groups were 69.4, 64.4 and 50.3%,
respectively (Fig. 2A). ACR50/70 response rates at week
104 in the secukinumab 300, 150 and 75 mg groups were
50.6%/33.1%, 36%/23.1% and 28.2%/14.9%, respect-
ively (Fig. 2B and C). At week 104, PASI 75/90 response
rates in the secukinumab 300, 150 and 75 mg groups
were 79.5%/69.6%, 73.3%/52.5% and 58.4%/33.7%, re-
spectively (Table 1). Secukinumab demonstrated efficacy
across multiple clinically relevant domains of PsA out-
comes, including DAS28-CRP, resolution of dactylitis
and enthesitis and improvement in SF-36 PCS and
HAQ-DI scores sustained through week 104 (Table 1).
Clinical responses with secukinumab were sustained
through week 104 in anti-TNF-a-naive patients and anti-
TNF-a-IR. Greater ACR20/50/70 response rates were
seen in TNF-a-IR patients receiving higher secukinumab
doses. ACR20 response rates at week 104 in anti-TNF-a-
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naive patients were 74.8, 79.3 and 62.7% with secukinu-
mab 300, 150 and 75 mg, respectively; corresponding
rates in anti-TNF-a-IR patients were 58.4, 38.9 and
26.3%, respectively (Fig. 3). ACR20 response rates at
week 104 in concomitant MTX patients were 70.6, 69.6
and 54.1% with 300, 150 and 75 mg, respectively; corres-
ponding rates in patients not taking MTX were 68.5, 59.8
and 45.8%, respectively (Fig. 4).
PROs and QoL
The HAQ-DI scores and SF-36 PCS scores improved sig-
nificantly in the secukinumab dose groups vs placebo at
week 24 [18]; improvements were sustained in the secu-
kinumab dose groups up to week 104 (Table 1). For the
SF-36 MCS scores, improvements from baseline at week
24 were better in the secukinumab dose groups vs pla-
cebo; further improvements were observed at week 104
with secukinumab (supplementary Table S1, available at
Rheumatology Online).
Least squares mean changes from baseline in patient
global assessment of disease activity and patient assess-
ment of PsA pain by VAS were higher in the secukinumab
dose groups compared with placebo at week 24 and im-
proved further at week 104 with secukinumab doses.
Secukinumab resulted in better improvements from
baseline in PsA QoL, Work Productivity And Activity
ImpairmentGeneral Health, Dermatology Life Quality Index,
Functional Assessment of Chronic Illness TherapyFatigue
and EQ-5D scores at week 24 compared with placebo.
Sustained or further improvements in these scores were
observed with secukinumab at week 104. In patients who
were employed, the decrease from baseline at week 24 in
the percentage work time missed and work impairment due
to health was higher with secukinumab doses vs placebo
(supplementary Table S1, available at Rheumatology Online).
Safety
Over the treatment period [mean (S.D.) exposure to secu-
kinumab of 709 (211.0) days] the incidence, type and se-
verity of AEs were consistent with those reported
previously by week 52 [19]. Over the entire treatment
period, the EAIRs of AEs were 163.3, 181.2 and 159.2
per 100 patient-years for patients who received at least
1 dose of secukinumab 300, 150 and 75 mg, respectively.
Discontinuations due to AEs in these three secukinumab
dose groups occurred at rates of 3.4, 5.6 and 5.1%,
respectively. No deaths were reported in the study.
FIG. 1 Patient flow through the study from randomization to week 104
All patients who were randomly allocated to treatment were included in the analysis of efficacy parameters at weeks 24,
52 and 104.
1996 www.rheumatology.oxfordjournals.org
Iain B. McInnes et al.
FIG. 2 ACR20, ACR50 and ACR70 response rates up to week 104
Data summaries until week 104 are based on multiple imputation as applied to missing variables. ACR20: at least 20%
improvement in the ACR response criteria; ACR50: at least 50% improvement in the ACR response criteria; ACR70: at
least 70% improvement in the ACR response criteria.
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In particular, no case of suicide or suicidal ideation was
reported in secukinumab-treated patients.
Infections and infestations were the most commonly re-
ported AE with secukinumab, with an EAIR of 65.0/100
patient-years across the three dosage groups. The most
common AEs by preferred term were upper respiratory
tract infection (13.6/100 patient-years) and nasopharyngi-
tis (12.6/100 patient-years). AEs were mostly mild or mod-
erate in severity. The EAIRs of serious AEs were 7.0, 5.6
and 7.7 per 100 patient-years for patients who received at
least one dose of secukinumab 300, 150 and 75 mg, re-
spectively (Table 2).
In the study cohort of secukinumab-treated patients,
the EAIRs for serious infections, Candida infections, IBD,
malignant/unspecified tumours and major adverse cardiac
events (MACEs) were 1.6, 2.3, 0.5, 1.3 and 0.3, respect-
ively. No new cases of tuberculosis were reported and no
reactivation of latent tuberculosis occurred. Non-serious
Candida infections over the entire treatment period were
reported for 17 (4.4%) patients across the three secukinu-
mab dose groups. These included 10 patients with oral
candidiasis, 5 patients with vulvovaginal candidiasis and 1
patient each with oesophageal Candida and intertrigo
Candida. All cases of Candida were mild or moderate in
severity and resolved with antifungal treatment and all pa-
tients continued in the study.
Crohn’s disease was not reported as an AE in any pa-
tient during the entire treatment period. Two cases of ul-
cerative colitis (one each in the 300 and 150 mg groups)
and one case each of haemorrhagic diarrhoea (300 mg
group) and anal fistula (300 mg group) were reported
with secukinumab. Of the two cases of ulcerative colitis
reported with secukinumab, one was a flare in a patient
with prior history and the other was a new onset. In the
secukinumab groups over the entire treatment period, four
cases of basal cell carcinoma, three cases of squamous
TABLE 1 Summary of efficacy results at week 104
Efficacy endpoint
Missing values considered Observed data
Secukinumab
300 mg
Secukinumab
150 mg
Secukinumab
75 mg
Secukinumab
300 mg
Secukinumab
150 mg
Secukinumab
75 mg
Patients randomized to secukinumab, n 100 100 99 100 100 99
ACR response
Overall population
Patients, n 100 100 99 84 77 67
ACR20 response, % 69.4 64.4 50.3 73.8 72.7 62.7
ACR50 response, % 50.6 36.0 28.2 56.0 42.9 37.3
ACR70 response, % 33.1 23.1 14.9 38.1 28.6 20.9
Anti-TNF-a-naive
Patients, n 67 63 65 56 53 51
ACR20 response, % 74.8 79.3 62.7 80.4 86.8 68.6
ACR50 response, % 58.5 46.1 38.0 66.1 50.9 43.1
ACR70 response, % 39.5 30.1 21.2 46.4 34.0 25.5
Anti-TNF-a-IR
Patients, n 33 37 34 28 24 16
ACR20 response, % 58.4 38.9 26.3 60.7 41.7 43.8
ACR50 response, % 34.1 18.9 9.4 35.7 25.0 18.8
ACR70 response, % 19.7 11.3 3.0 21.4 16.7 6.3
PASI responsea
Patients, n 41 58 50 36 47 38
PASI 75 response, % 79.5 73.3 58.4 80.6 78.7 63.2
PASI 90 response, % 69.6 52.5 33.7 72.2 59.6 34.2
DAS28-CRP
Patients, n 100 100 99 83 77 66
Change from baselineb 1.9 (0.1) 1.7 (0.1) 1.5 (0.1) 2.0 (1.2) 1.8 (1.1) 1.7 (1.4)
Dactylitis resolutionc 46 32 33 87 77 68
Resolution rate, % 79.9 78.0 88.6 88.5 92.2 95.6
Enthesitis resolutionc 56 64 68 87 77 68
Resolution rate, % 71.5 61.8 68.4 77.0 70.1 69.1
SF-36 PCS
Patients, n 100 100 99 85 79 66
Change from baselineb 6.8 (0.9) 5.0 (0.9) 4.1 (0.9) 7.4 (9.4) 5.6 (8.0) 5.6 (8.4)
HAQ-DI
Patients, n 100 100 99 86 77 67
Change from baselineb 0.6 (0.1) 0.5 (0.1) 0.3 (0.1) 0.6 (0.6) 0.6 (0.5) 0.3 (0.6)
aEvaluated in subgroup with >3% of BSA affected by psoriatic skin involvement. bMean (S.D.) (observed data) or least squares
mean (S.E.) (mixed-effects model for repeated measures estimates). cEvaluated in the subgroup with these symptoms at
baseline.
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cell carcinoma and one case each of Bowen’s disease,
squamous cell carcinoma of the tongue and throat cancer
were reported. No other malignancies were reported in
the entire treatment period. One adjudicated MACE was
reported during the 24 week analysis (myocardial infarc-
tion) in a patient on secukinumab 75 mg with a history of
sinus tachycardia, ongoing hypertension and hyperlipid-
aemia. A case of haemorrhagic stroke was reported after
the 24 week analysis in a patient on secukinumab 300 mg
and was adjudicated as a MACE. One case of uveitis was
reported in a patient randomized to secukinumab 300 mg,
which was moderate in severity and the patient recovered
without any intervention. No changes were necessitated
to the study treatment regimen in this patient.
Transient Common Terminology Criteria for AEs grade
3 neutropenia occurred in two patients (300 mg group)
over the entire treatment period. No patient withdrew
from the study because of neutropenia. Treatment-
emergent anti-secukinumab antibodies were detected in
three patients, two patients originally allocated to secuki-
numab 150 mg and one originally allocated to placebo
and switched to secukinumab 150 mg at week 16.
Immunogenicity-related AEs or loss of efficacy were not
reported in these patients.
FIG. 3 ACR20, 50 and 70 response rates by baseline TNF status at weeks 24, 52 and 104
y
P < 0.0001;
yy
P < 0.001;
yyy
P < 0.01; *P < 0.05. P-values at week 24 derived from a logistic regression model with
treatment as the factor and baseline weight as a covariate. Missing data were imputed as non-response until week 52.
Data until week 52 were reported previously [18]. Data for week 104 are after multiple imputation applied to missing
variables. ACR20: at least 20% improvement in the ACR response criteria; ACR50: at least 50% improvement in the ACR
response criteria; ACR70: at least 70% improvement in the ACR response criteria; MI: multiple imputation; NRI: non-
responder imputation.
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Discussion
In phase 3 trials, secukinumab showed rapid-onset effi-
cacy in the treatment of psoriasis and PsA [4, 18]. The two
pivotal phase 3 studies investigating secukinumab in PsA,
namely, FUTUREs 1 and 2, suggested that secukinumab
is associated with a wide range of clinical benefits across
outcome domains.
Whereas the primary results of the FUTURE 2 study
showed that secukinumab was efficacious in patients with
PsA, the current dataset demonstrates that the reported
improvements in clinical outcomes with secukinumab in
PsA were either sustained or further improved through
104 weeks of therapy in those patients remaining in the
study. Secukinumab showed efficacy across multiple clinic-
ally relevant domains of PsA, including PASI 75/90 response
rates, DAS28-CRP, resolution of dactylitis and enthesitis,
SF-36 PCS and HAQ-DI score through week 104, consistent
with the clinical benefits reported previously at weeks 24
and 52 [18]. The notable responses in PASI score and
enthesitis are consistent with the proposed relationship of
the IL-23/17 pathway to the skinenthesial axis [23].
Discontinuations were low with secukinumab and sus-
tainability on the study drug over the long term was
FIG. 4 ACR20, ACR50 and ACR70 response rates by baseline MTX use at weeks 24, 52 and 104
y
P< 0.0001;
yy
P< 0.001;
yyy
P< 0.01; *P < 0.05. P-values at week 24 derived from a logistic regression model with
treatment as the factor and baseline weight as a covariate. Missing data were imputed as non-response until week 52.
Data until week 52 are reported previously [18]. Data for week 104 is after multiple imputation applied to missing variable.
ACR20: at least 20% improvement in the ACR response criteria; ACR50: at least 50% improvement in the ACR response
criteria; ACR70: at least 70% improvement in the ACR response criteria; MI: multiple imputation; NRI: non-responder
imputation.
2000 www.rheumatology.oxfordjournals.org
Iain B. McInnes et al.
notable in the present study, particularly in the 300
and 150 mg groups (86 and 76%, respectively), which
is likely a reflection of the efficacy and tolerability of
secukinumab.
The clinical responses with secukinumab were noted in
both anti-TNF-a-naive and anti-TNF-a-IR patients, with
responses generally greater in the anti-TNF-a-naive popu-
lation for all doses of secukinumab. The response rates
were markedly higher in the secukinumab 300 mg group
compared with the 150 and 75 mg groups in the anti-TNF-
a-IR patients, suggesting a dose response in these pa-
tients. However, the study was not powered to detect
statistically significant differences between the doses.
Improvements with secukinumab through 104 weeks
were similar in both concomitant MTX and without MTX
subgroups.
PsA places a substantial burden on patients, diminish-
ing their capacity to carry out daily activities and reducing
their health-related QoL. Therapies that improve these as-
pects of disease have the potential to reduce the broad
burden of PsA and also reduce its impact on work prod-
uctivity. Consistent with observations in other similar
studies [2426], patients in the FUTURE 2 study had
impaired physical function, work productivity and health-
related QoL at baseline. In this study, at week 24, secu-
kinumab demonstrated clinically meaningful improve-
ments in PROs, including global disease activity, pain,
physical function, fatigue and generic and disease-spe-
cific measures of health-related QoL in patients with
active PsA. The improvements in PRO scores with
secukinumab were maintained or improved further at
week 104.
Sustained improvements in joint and skin symptoms,
physical function and QoL of patients with PsA observed
after treatment with secukinumab 300 and 150 mg
through 2 years suggest the potential for selection of IL-
17 blockade in discrete phenotypes of PsA, such as pa-
tients with dominant enthesitis or significant concomitant
psoriasis. Such possibilities should now be subject to in-
vestigation. These longer-term efficacy data are import-
ant, as they suggest the potential for expansion of the
treatment armament for PsA.
The safety profile of secukinumab was consistent with
that in previous reports on PsA [18] and psoriasis [4]. The
types, severity, nature and incidence of AEs with secuki-
numab at week 104 were similar to those reported for the
placebo-controlled period and at week 52 [19], with no
apparent relation to the dose. The overall incidence of
SAEs was low and did not show dose dependence
across secukinumab dose groups. The rate of discontinu-
ation because of AEs with secukinumab was low and no
deaths occurred during the study. Immunogenicity with
secukinumab was low and was not associated with a
loss of efficacy or immunogenicity-related AEs.
The lack of a long-term comparator arm was a limitation
of the study, although continuation of a placebo arm in the
long term would be unethical. Statistical analysis of the
data obtained at week 24 differed from that at weeks 52
and 104 since all patients originally randomized to pla-
cebo had switched to secukinumab by week 24.
TABLE 2 Summary of safety data at week 104
Variable
Secukinumab
300 mg (n = 145)
Secukinumab
150 mg (n = 143)
Secukinumab
75 mg (n = 99)
Any secukinumab
(n = 387)
Duration of exposure, days, mean (S.D.) 726.0 (190.1) 715.5 (196.0) 674.8 (254.8) 709.0 (211.0)
Exposure, patient-years 288.2 280.1 182.9 751.3
EAIR/100 patient-years, n
Any AE 127 (163.3) 126 (181.2) 84 (159.2) 337 (168.5)
Any SAEs 19 (7.0) 15 (5.6) 13 (7.7) 47 (6.6)
Death 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Discontinuation due to AEsa 5 (3.4) 8 (5.6) 5 (5.1) 18 (4.7)
Common AEs, n (EAIR/100 patient-years)b
Upper respiratory tract infection 33 (13.4) 30 (12.7) 23 (15.6) 86 (13.6)
Nasopharyngitis 28 (11.3) 33 (13.7) 21 (13.1) 82 (12.6)
Diarrhoea 12 (4.4) 13 (4.9) 11 (6.3) 36 (5.0)
Headache 10 (3.7) 15 (5.7) 5 (2.9) 30 (4.2)
Nausea 9 (3.2) 12 (4.5) 7 (4.0) 28 (3.9)
Urinary tract infection 10 (3.6) 12 (4.5) 6 (3.4) 28 (3.9)
Vomiting 7 (2.5) 7 (2.6) 4 (2.3) 18 (2.5)
AEs of special interest, n (EAIR/100 patient-years)
Serious infections 6 (2.1) 5 (1.8) 1 (0.6) 12 (1.6)
Candida infections 8 (2.9) 8 (2.9) 1 (0.5) 17 (2.3)
Ulcerative colitis 1 (0.3) 1 (0.4) 0 (0.0) 2 (0.3)
Neutropenia 1 (0.3) 0 0 1 (0.1)
Malignancy/unspecified tumour 1 (0.3) 6 (2.2) 3 (1.7) 10 (1.3)
MACE 1 (0.3) 0 (0.0) 1 (0.6) 2 (0.3)
aEAIR was not calculated for study drug discontinuations due to AEs; percentages are shown instead. bAEs with incidence of
at least 2.0 cases per 100 patient-years in the combined secukinumab group during the entire treatment period.
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In summary, secukinumab provided sustained improve-
ments at 2 years across multiple clinical domains, includ-
ing joint and skin, dactylitis and enthesitis, improved
physical functioning and QoL in patients with active PsA.
The safety profile of secukinumab showed no new or un-
expected safety signals through 2 years of treatment.
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